QUICK LINKS:

EFS

Gene-to-Protein & Gene-to-Structure

Viva Engine for Lead Discovery

Membrane Protein Targeted Discovery Technology

请拖入内容到容器

EFS

Viva BioInnovator as the core division of EFS...

Gene-to-Protein & Gene-to-Structure

Viva Biotech is the world's top CRO specialized in ...

Viva Engine for Lead Discovery

A unique platform for drug lead discovery from target to drug candidates consisting of:
请拖入内容到容器

Antibody

Viva is devoted to pushing the boundary of GPCR protein studies. Working closely with experienced experts from GPCR field, well trained researchers in Viva Biotech are able to deliver top quality Cry
View details

Cell Lines

GPCR cell lines developed in-house are ready for distribution and assay screening services.
View details

Crystal Structures

Crystal structures developed in-house are ready for distribution, which can be used for compound soaking.
View details
请拖入内容到容器
Viva Biotech and Langhua Pharmaceutical Reached the Strategic Acquisition Agreement, Accelerating the Integration and Escalation of the Service Chain of Innovative Drug Industry
August 8th, 2020, Viva Biotech (Shanghai) Co., Ltd. entered into the Share Purchase Agreement pursuant and the Vendors agreed to collectively sell 80% of the equity interest in Zhejiang Langhua Pharmaceutical Co., Ltd.
ABM Therapeutics has Completed A + Round Financing of 20 Million US Dollars
This round of financing will be used to accelerate the clinical research and development of ABM-1310 and several existing preclinical projects.
Dr. David Xu, Chief Business Officer of Viva Biotech: Innovative drugs must effectively address unmet clinical needs
“New breakthroughs in scientific research do not necessarily solve specific practical problems, but innovative drugs must effectively address clinical needs.”
请拖入内容到容器